Larimar Therapeutics (LRMR) announced the appointment of Jeffrey Sherman to the company’s board of directors, effective immediately. Sherman, currently executive VP, chief medical officer, or CMO, at Horizon Therapeutics (HZNP), has over 20 years of executive experience in regulatory and clinical strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LRMR:
- Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
- Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
- Larimar Therapeutics expects cash to fund operations into 4Q24
- Larimar Therapeutics reports Q2 EPS (19c), consensus (19c)
- Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results